Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting

Mirati Therapeutics Inc's MRTX SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis.
SAPPHIRE is a Phase 3 study evaluating sitravatinib plus Bristol-Myers Squibb Co's BMY Opdivo (nivolumab) versus docetaxel in patients with second or third-line advanced non-squamous non-small cell lung cancer who progressed on prior therapy.
The company plans to disclose the study data at a future date.
Principal Investigators will be given the option to continue therapy for patients experiencing clinical benefit and who would like to remain on treatment.
BeiGene Ltd BGNE paid Mirati $10 million upfront in 2018 for exclusive rights in the Asia-Pacific region, with another $123 million in milestone payments and sales-based royalties.
In 2019, Mirati Therapeutics announced a clinical collaboration with Bristol-Myers to evaluate the combination of sitravatinib and nivolumab.
In December, the FDA granted accelerated approval to Mirati's Krazati (adagrasib), a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
Price Action: MRTX shares are trading 6.48% lower at $41 during the premarket session on the last check Thursday.

Momentum35.26

Growth66.60

QualityNot Available

Value30.88

Short

Medium

Long